LiuHZhaYDingC, et al.AST to ALT ratio and peripheral artery disease in Chinese hypertensive population: a cross-sectional study. Angiology. 2021;72:916–22.
MuzurovićEMMikhailidisDP. Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment Options. J Cardiovasc Pharmacol Ther. 2021;26:25–39.
4.
WengSFKaiJGuhaINQureshiN. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart. 2015;2:e000272.
5.
EwidMSherifHAllihimyAS, et al.AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020;13:178.
6.
YokoyamaMWatanabeTOtakiY, et al.Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up. Dis Markers. 2016;2016:4857917.
7.
RiefPPichlerMRaggamR, et al.The AST/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Medicine (Baltimore). 2016;95:e3843.
8.
LiuYZhaoPChengM, et al.AST to ALT ratio and arterial stiffness in non-fatty liver Japanese population: a secondary analysis based on a cross-sectional study. Lipids Health Dis. 2018;17:275.
9.
VonbankASaelyCReinP, et al.The alanine aminotransferase/aspartate aminotransferase ratio predicts future cardiovascular events in patients with established coronary artery disease and homa insulin resistance. Atherosclerosis. 2016;252:e64–5.
10.
ZouYLiXWangC, et al.Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J. 2017;47:1147–53.
11.
TargherGBertoliniLPadovaniR, et al.Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006;23:403–9.
12.
HanleyAJWilliamsKFestaAWagenknechtLED’AgostinoRBJrHaffnerSM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–7.
13.
McPhersonSStewartSFHendersonEBurtADDayCP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–9.
14.
LongMTPedleyAMassaroJMHoffmannUFoxCS. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One. 2016;11:e0157517.
15.
KatsikiNPerez-MartinezPAnagnostisPMikhailidisDPKaragiannisA. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?Curr Vasc Pharmacol. 2018;16:219–27.
16.
MuzurovićEMikhailidisDPMantzorosC.Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism. 2020;109:154305.
17.
RochlaniYPothineniNVKovelamudiSMehtaJL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11:215–25.
18.
KooBKAllisonMACriquiMHDenenbergJOWrightCM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg. 2020;71:204–11.e4.
19.
KatsikiNAthyrosVGMikhailidisDP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?Curr Vasc Pharmacol. 2016;14:432–41.
20.
MuzurovićEStankovićZKovačevićZŠkrijeljBŠMikhailidisDP. Inflammatory Markers Associated With Diabetes Mellitus - Old and New Players. Curr Pharm Des. 2020; doi:10.2174/1381612826666201125103047 Epub ahead of print
